Incyte (INCY) Biosciences Japan G.K. announced that Japan’s Ministry of Health, Labour and Welfare has approved Minjuvi in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. “This approval represents the second regulatory approval for Minjuvi in Japan. Minjuvi in combination with rituximab and lenalidomide was previously approved by the MHLW for the treatment of adult patients with relapsed or refractory follicular lymphoma,” the company stated.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on INCY:

Disclaimer & DisclosureReport an Issue